Peptide Comparison
PT-141 vs Melanotan I
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
This combination is flagged
Melanotan II combined with novel peptides during dose-finding: High risk per peptide research literature. Masks individual peptide response (pigmentation, nausea, BP overlap); MC1R activation raises melanoma/mole darkening concerns when dose-finding other compounds.
Data-derived verdict
PT-141 and Melanotan I share the melanocortin class and carry roughly equivalent evidence (FDA-Approved / FDA/EMA-Approved). On the catalogued data layer PT-141 has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; PT-141's evidence base is currently denser.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Shared safety considerations
Both compounds share these reported concerns: nausea. Open each peptide page for the full risk paragraph and source citations.
Side-by-side
| PT-141 | Melanotan I | |
|---|---|---|
| Class | Melanocortin receptor agonist (FDA-approved) | MC1R agonist; EU/FDA-approved for EPP |
| Drug class | Sexual-Health | Dermatologic |
| Mechanism | MC4R agonist in CNS; induces sexual desire independent of vascular mechanisms | Selective MC1R agonist; stimulates eumelanin production without sexual effects of MT-II |
| Route | SC / Intranasal | SC implant |
| Half-life | ~2 hrs | Implant (sustained release) |
| Dosage (research) | 1.75 mg SC 45 min before sex (FDA label) | 16 mg SC implant every 2 months |
| Evidence tier | FDA-Approved | FDA/EMA-Approved |
| Research depth | 99 indexed | 101 indexed |
| Availability | Prescription | Prescription (EPP) |
| Reported risks | Nausea (~40%); flushing; headache; transient BP increase; focal hyperpigmentation | Injection site reactions; fatigue; nausea; melanin darkening |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick PT-141 or Melanotan I?
PT-141 and Melanotan I share the melanocortin class and carry roughly equivalent evidence (FDA-Approved / FDA/EMA-Approved). On the catalogued data layer PT-141 has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; PT-141's evidence base is currently denser.
What is the difference between PT-141 and Melanotan I?
PT-141 is classed as Melanocortin receptor agonist (FDA-approved); Melanotan I is classed as MC1R agonist; EU/FDA-approved for EPP. Reported mechanism: PT-141, MC4R agonist in CNS; induces sexual desire independent of vascular mechanisms; Melanotan I, Selective MC1R agonist; stimulates eumelanin production without sexual effects of MT-II. Reported half-life: PT-141, ~2 hrs; Melanotan I, Implant (sustained release). Routes in published studies: PT-141, SC / Intranasal; Melanotan I, SC implant.
Which has stronger evidence, PT-141 or Melanotan I?
PT-141 and Melanotan I sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. PT-141 is graded FDA-Approved, with 6 cited sources on its reference page and 99 indexed studies. Melanotan I is graded FDA/EMA-Approved, with 2 cited sources on its reference page and 101 indexed studies.
Which is more accessible, PT-141 or Melanotan I?
Both PT-141 and Melanotan I are FDA-approved drugs. Catalog status: PT-141, Prescription; Melanotan I, Prescription (EPP).
Are PT-141 and Melanotan I ever combined?
PT-141 and Melanotan I appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…